{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010315","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.226725+00:00","generated_at":"2026-06-17T08:03:46.701424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AgeX Therapeutics reports FY2022 net loss of $10.5M; cash only $0.7M, substantial doubt about going concern","bullets":["Net loss of $10.5M ($0.28 per share) in FY2022 vs $8.7M ($0.23) in FY2021.","Cash and restricted cash only $0.7M; owes Juvenescence $21.4M in loans.","Substantial doubt about ability to continue as a going concern for next 12 months.","Operating expenses fell to $7.0M from $8.2M; R&D decreased to $1.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010315","json":"https://secwatch.observer/filing/0001493152-23-010315.json","markdown":"https://secwatch.observer/filing/0001493152-23-010315.md","text":"https://secwatch.observer/filing/0001493152-23-010315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/0001493152-23-010315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:03:46.701424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7417be1efa64126ba18e3d80d5a2d10e488d2bd5","claim":"Serina Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total, net income Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million, EPS ($0.28) per share (basic and diluted).","evidence_excerpt":"AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/0001493152-23-010315-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Revenue","value":"Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total"},{"label":"Net income","value":"Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million"},{"label":"EPS","value":"($0.28) per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}